ArticleJournal of cachexia, sarcopenia and muscle2025
Restoring Muribaculum intestinale-Derived Butyrate Mitigates Skeletal Muscle Loss in Cancer Cachexia.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Spatiotemporal dynamics of the host-tumor metabolic interface: Implications for precision nutritional oncology.Genes & diseases · 2026Review
- Genome-wide association study of sarcopenia index reveals sex-stratified genetic architecture.Biology of sex differences · 2026Article
- A Probiotic Mixture Neuralli™-CORE Attenuates DSS-Induced Colitis by Enhancing Gut Microbiota Resilience in Mice.International journal of molecular sciences · 2026Article
- Article
- Antibiotic course frequency and recovery strategies alter gut microbial composition and metabolism.ISME communications · 2026Article
- Review
- Restoring Muribaculum intestinale-Derived Butyrate Mitigates Skeletal Muscle Loss in Cancer Cachexia.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundMuscle wasting in cancer cachexia patients is a major clinical challenge. Although reduced levels of short-chain fatty acids (SCFAs) in cachexia patients have been associated with muscle atrophy, their precise role remains unclear. Given that the gut microbiota is the primary source of SCFAs, modulating SCFA composition through probiotic supplementation has shown promise in preclinical studies of cancer cachexia. In this study, we aimed to elucidate the dysregulation of the gut microbiota in cachexia mice and investigate the potential protective effect of supplementation with the inulin diet, Muribaculum intestinale (MI) and sodium butyrate (NaB) against cachexia-induced muscle wasting.
methodsWe analysed the gut microbiota composition using 16S rRNA gene amplicon sequencing and measured SCFA levels to evaluate metabolic changes in faecal samples from cancer cachexia models. We identified the associations between the microbiota and metabolites and evaluated the impacts of MI (10
resultsFaecal analysis in cachectic mice revealed a significant alteration in gut microbiota composition, particularly a reduction in Muribaculaceae (76.0%) and Muribaculum intestinale (82.0%). Direct supplementation with MI increased its abundance and butyrate level (p < 0.05), reducing muscle wasting in cachexia. Correlation analysis underscored a significant positive association between Muribaculaceae, Muribaculum intestinale and butyrate levels (p < 0.05). NaB also ameliorated muscle wasting, with RNA-Seq of muscle tissues showing a decrease in inflammatory factors and autophagy, downregulation of pyruvate dehydrogenase kinase 4 (Pdk4) expression (61.6%) and increased ATP content (25.5%), thereby playing a pivotal role in attenuating muscle degradation in cancer cachexia. Supplementation with inulin diet increased the levels of Muribaculaceae and Muribaculum intestinale (p < 0.05), also alleviating cachexia symptoms in mice.
conclusionsIn cachectic mouse models, Muribaculaceae and Muribaculum intestinale are reduced and exhibit a significant positive correlation with SCFA butyrate. Inulin or MI supplementation increased these bacteria, ameliorating cachexia. NaB attenuates muscle wasting through coordinated modulation of autophagy suppression, anti-inflammatory effects and metabolic reprogramming (including PDK4 downregulation and ATP elevation), collectively indicating the existence of a gut-muscle axis in cachexia progression. These findings underscore the potential of microbiota-targeted interventions in managing cancer cachexia and highlight the intricate interplay between gut microbiota and skeletal muscle health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.